If you have Crohn’s disease or ulcerative colitis, you have probably noticed that a treatment that works well for one person may do very little for another. Even when two people share the same diagnosis and similar symptoms, their response to the same medication or diet can be entirely different. This variability is not random. It reflects fundamental differences in genetics, immune signalling, gut bacteria, disease location, and the way inflammation behaves in each person’s body.
The Nature of IBD Is Highly Individual
Inflammatory bowel disease (IBD) is not a single condition with a single cause. It groups together chronic inflammatory disorders of the gut, but the underlying drivers vary widely between individuals. Crohn’s disease can affect any part of the digestive tract and may involve different layers of the gut wall, while ulcerative colitis is limited to the colon and affects only the innermost lining. Even within these categories, the distribution, severity, and behaviour of inflammation differ. Some people develop strictures or fistulas, others do not. Some have predominantly immune-driven inflammation, while in others, microbial imbalance or barrier dysfunction plays a larger role. These differences shape how each person responds to treatment.
Genetic Variation Influences Drug Response
Your genes influence not only your risk of developing IBD but also how your body processes and responds to medication. Variations in genes encoding drug-metabolising enzymes can alter how quickly a drug is broken down or activated. For example, thiopurine drugs such as azathioprine rely on the enzyme thiopurine methyltransferase (TPMT) for metabolism. People with low TPMT activity may experience toxicity at standard doses, while those with high activity may not achieve adequate drug levels. Similarly, genetic differences in immune pathways, such as those involving tumour necrosis factor (TNF) or interleukin receptors, can affect whether a biologic therapy targeting those pathways will be effective. Pharmacogenomics, the study of how genes affect drug response, is increasingly used to guide treatment choices, but it is not yet routine in all centres.
Disease Location and Behaviour Matter
Where inflammation occurs and how it behaves over time significantly affect treatment outcomes. In Crohn’s disease, inflammation in the ileum may respond differently to therapy than inflammation in the colon or upper gastrointestinal tract. Penetrating disease, which involves fistulas or abscesses, often requires a different approach than purely inflammatory disease. In ulcerative colitis, the extent of inflammation influences both the type of treatment used and the likelihood of response. Topical therapies such as rectal foams or suppositories work well for distal disease but are insufficient for more extensive inflammation. Surgery may alter the gut environment and change how subsequent therapies work.
The Immune System Varies Between People
IBD involves a dysregulated immune response, but the specific immune pathways that drive inflammation differ from person to person. Some individuals have disease driven primarily by TNF, a pro-inflammatory signalling molecule. In these cases, anti-TNF biologics such as infliximab or adalimumab are often effective. Others may have inflammation driven more by interleukin-12 and interleukin-23, pathways targeted by drugs like ustekinumab. Still others may respond better to therapies that block gut-specific integrins, such as vedolizumab, which prevents immune cells from entering intestinal tissue. There is no simple test to predict which pathway is dominant in a given person, so treatment often involves trial and observation. Over time, the immune system can also adapt, leading to loss of response even to a previously effective drug.
The Gut Microbiome Plays a Role
The trillions of bacteria, viruses, and fungi that live in your gut, collectively known as the microbiome, influence inflammation and treatment response. Some bacterial strains produce short-chain fatty acids that help regulate immune function and maintain the gut barrier. Others may promote inflammation or interfere with drug metabolism. Differences in microbial composition can affect how well a drug works and how well the gut heals. Antibiotic use, diet, stress, and previous infections all shape the microbiome, and these factors vary widely between individuals. Research is beginning to identify specific microbial signatures associated with treatment response, but translating this into clinical practice remains a work in progress.
Drug Levels and Immune Reactions to Biologics
Even when a drug is the right choice for a particular immune pathway, the dose reaching the tissue must be sufficient. Some people clear drugs more rapidly than others due to differences in metabolism, body weight, or the presence of anti-drug antibodies. Biologics, which are protein-based therapies, can trigger the immune system to produce antibodies against the drug itself. These antibodies can reduce drug levels or block the drug from working, a phenomenon known as immunogenicity. Therapeutic drug monitoring, which measures drug levels and antibodies in the blood, is now used routinely to optimise biologic therapy and distinguish between true treatment failure and inadequate dosing.
Previous Treatments and Disease Duration
The longer inflammation persists, the more likely it is to cause structural damage to the gut, including fibrosis (scarring) and changes to the muscle and nerve layers. Once fibrosis has developed, anti-inflammatory drugs may have limited benefit because the problem is no longer purely inflammatory. People who have had IBD for many years or who have been treated with multiple therapies may also have more treatment-refractory disease. This is one reason why earlier and more effective treatment is increasingly favoured, aiming to control inflammation before irreversible damage occurs.
Lifestyle and Environmental Factors
Diet, sleep, stress, smoking, and other lifestyle factors influence gut inflammation and treatment outcomes. Smoking worsens Crohn’s disease but may paradoxically improve ulcerative colitis, though it is never recommended due to broader health risks. Stress does not cause IBD, but it can worsen symptoms and may influence immune activity. Diet affects the microbiome, gut barrier integrity, and inflammatory signalling, although the optimal diet varies between individuals. These factors interact with medication, sometimes enhancing or undermining its effect.
Practical Takeaways
- Treatment response in IBD is influenced by genetics, disease location, immune pathways, the microbiome, drug levels, and lifestyle factors.
- No single test currently predicts which treatment will work best for a given person, so finding the right therapy often involves trial, monitoring, and adjustment.
- Therapeutic drug monitoring can help optimise biologic therapy by ensuring adequate drug levels and identifying anti-drug antibodies.
- Early and effective treatment is important to prevent structural damage that may reduce responsiveness to therapy later.
- Consistency with medication, follow-up appointments, and open communication with your clinical team improve the chances of finding a treatment that works.
Conclusion
The variability in treatment response reflects the complexity of IBD itself. Each person’s disease is shaped by a unique combination of genetic, immunological, microbial, and environmental factors. Understanding this variability helps explain why finding the right treatment can take time and why regular monitoring and adjustment are part of long-term management. Advances in precision medicine, including genetic testing, microbiome analysis, and therapeutic drug monitoring, are gradually improving the ability to match treatments to individuals. In the meantime, patience, persistence, and close collaboration with your healthcare team remain essential.
References
- Vermeire S, Gils A, Accverenighe P, et al. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. doi:10.1177/1756283X17750355
- Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020;158(1):189-199. doi:10.1053/j.gastro.2019.09.041
- Ananthakrishnan AN. Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci. 2015;60(2):290-298. doi:10.1007/s10620-014-3350-9
- Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20(8):970-979. doi:10.1038/s41590-019-0415-0
- Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320-1329. doi:10.1053/j.gastro.2015.02.031
- Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489-1499. doi:10.1053/j.gastro.2014.02.009
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.